Andrew is counsel at Fineberg Ramamoorthy LLP. Andrew’s practice focuses exclusively in the life sciences arena where he assists companies to navigate and overcome complex legal and regulatory challenges, including under the Patented Medicines (Notice of Compliance) Regulations. With over a decade of litigation experience, and relying heavily on a client-centric attitude and deep knowledge and understanding of the pharmaceutical industry, Andrew provides high quality advice to, and advocacy on behalf of, his clients involved in high stakes pharmaceutical litigation. Andrew takes great pride in building strong relationships with his clients, which enables them to work together to find better solutions and allows him to contribute meaningfully to the success of their businesses.

Andrew draws on a wealth of experience, having previously worked for a U.S. State Department of Public Health (Division of Food and Drug), hospital, retail community and specialty pharmacies, a leading American biopharmaceutical company (Division of Regulatory Strategy and Intelligence), and leading national and boutique law firms in Canada. Through these experiences, and as a lawyer and pharmacist licensed to practice in Canada and the U.S., Andrew has acquired substantial knowledge and expertise on issues of importance to companies operating in the life sciences industry.

  • Admitted to the Massachusetts State Bar, 2003
  • Admitted to the Ontario Bar, 2006
  • Member, Massachusetts Board of Pharmacy, 1998
  • Member, Ontario College of Pharmacists (Part A, can provide patient care), 2005
  • J.D., Concentration Certificate in Health and Biomedical Law, Suffolk University Law School
  • B.Sc., Pharmacy, Massachusetts College of Pharmacy
  • Regulatory Affairs Certificate: Medical Devices and Pharmaceuticals (Dual), RAPS Online University
  • Life Sciences ‘Rising Star’ in Legal Media Group’s Expert Guides - Rising Stars (2015-2018)
  • Elected to The Rho Chi Honour Society, the academic honour society in pharmacy
  • Facts and Comparisons Award of Excellence in Clinical Communications
  • Apotex Inc. v. Schering Corporation, 2018 ONSC 6810
  • Apotex Inc. v AstraZeneca Canada Inc., 2018 FC 181
  • AstraZeneca Canada Inc. v. Mylan Pharmaceuticals ULC, 2017 FC 142
  • Apotex Inc. v. Eli Lilly and Company, 2015 ONSC 5396
  • Alcon Canada Inc. v. Apotex Inc., 2014 FC 791
  • Apotex Inc. v. Sanofi-Aventis, 2012 FC 553